Analysis of the size, share and trends of the pharmaceutical market in Tunisia 2021-2028 by formulation (tablets, injectables, sprays (BFS mode, non BFS mode) and suspensions, capsules, powders) –


DUBLIN – (COMMERCIAL THREAD)–The “Tunisian Pharmaceuticals Market Size, Share and Trends Analysis Report by Formulation (Tablets, Injectables, Sprays (BFS Mode, Non-BFS Mode), Suspensions, Capsules, Powders) and Segment Forecast, 2021-2028 “ report was added to offer.

The size of the Tunisian pharmaceutical market is estimated at 3.4 billion USD by 2028.

The market is expected to grow at a CAGR of 12.9% from 2021 to 2028. The market is largely driven by the improvement of pharmaceutical exports from Tunisia, which is the result of the expansion of the pool of local pharmaceutical manufacturers in the region. country. The country continues to explore and capitalize on export markets, primarily francophone countries in Africa.

Manufacturers are also engaged in on-site production in sub-Saharan African countries. For example, the Tunisian company Teriak acquired the Cameroonian Cinpharm factory at the end of 2015 to export to the markets of Central Africa. Despite the fact that Tunisian pharmaceutical companies have marked their presence in African markets, drug manufacturers face several challenges, including the lack of infrastructure allowing a direct air route, sea links or trade measures that hamper their growth. in African countries.

Some national companies have started producing drugs in West Africa in order to reduce import costs for countries in the region, which in turn gives a significant boost to the pharmaceutical industry in Tunisia. For example, Medis has been recognized as the company that exports to the largest number of countries. The company has collaborated with 11 countries. On the other hand, Teriak ranked second on the Tunisian private market in 2018 with an export development from 2% in 2012 to 13% in 2018.

The COVID-19 pandemic is expected to create lucrative opportunities for healthcare professionals looking to address the protracted challenges that persist in the pharmaceutical industry. Besides the pandemic, there is a high prevalence of several chronic diseases including heart disease, diabetes, obesity and respiratory ailments, which can affect all age groups.

This should open new avenues for healthcare professionals to develop innovative management strategies that can help reduce pre-existing pricing issues in the pharmaceutical industry and effectively combat them in the face of the pandemic.

Highlights of the Tunisian Pharmaceutical Market Report

  • An increase in cases of diabetes, cardiovascular disorders, obesity and respiratory diseases is expected to expand the pool of local drug manufacturers, thereby propelling the market growth

  • The tablet formulations segment accounted for the largest share of revenue in 2020, attributed to the ease of manufacture associated with these drug formulations.

  • The capsule formulations segment is expected to gain ground in the coming years in Tunisia, registering the highest CAGR by 2021 – 2028

  • Rising popularity of soft capsules in the pharmaceutical industry contributes to the growth of the segment

  • Blow-Fill-Seal (BFS) technology in injectables is increasingly used for pharmaceutical formulation and complements industry dynamics

  • Firms improve local manufacturing capabilities to compete in the market

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Tunisian pharmaceutical market: market summary

2.1 Market summary

Chapter 3 Tunisian pharmaceutical market: industry outlook

3.1 Market dynamics

3.1.1 Market Driver Analysis Increase in pharmaceutical R&D expenditure Focus on health care needs

3.1.2 Analysis of market restrictions Lack of solid reforms to regulate and standardize the pharmaceutical industry

3.1.3 Analysis of market opportunities Increase investment and financing programs

3.1.4 Analysis of market challenges Lack of qualified professionals

3.2 Business analysis: Tunisia

3.2.1 Export analysis

3.2.2 Import analysis

3.3 Business analysis: Middle East and Africa

3.4 Analysis of drug prices and affordability in Tunisia

3.5 Regulatory framework

3.6 Analysis of the pharmaceutical industry in Tunisia: impact analysis of COVID-19

3.7 SWOT analysis; By factor (political and legal, economic and technological)

3.8 Porter’s five forces analysis

Chapter 4 Prospects for pharmaceutical market formulation in Tunisia

4.1 Analysis of the Tunisian pharmaceutical industry: analysis of formulation movements

4.2 Tablets

4.3 Capsules

4.4 Injectable

4.4.1 Tunisian Pharmaceutical Industry Analysis for Injectable Estimates and Forecasts, 2017 – 2028 (USD Million)

4.4.2 BFS mode

4.4.3 Non-BFS mode

4.5 Sprays / Aerosol

4.5.1 Tunisian Pharmaceutical Industry Analysis for Sprays / Aerosol Estimates and Forecasts, 2017 – 2028 (USD Million)

4.5.2 BFS mode

4.5.3 Non-BFS mode

4.6 Suspension

4.6.1 Analysis of Tunisian pharmaceutical industry for suspensions estimates and forecasts, 2017 – 2028 (USD million)

4.6.2 BFS mode

4.6.3 Non-BFS mode

4.7 Powders

4.8 Other formulations

4.8.1 Analysis of Tunisian Pharmaceutical Industry for Estimates and Forecasts of Other Formulations, 2017 – 2028 (USD Million)

4.8.2 BFS mode

4.8.3 NON-BFS mode

Chapter 5 Competitive Landscape

5.1 Company Market Share Analysis (Top 10 Players)

5.2 Company profiles


  • Sanofi (sanofi-aventis Tunisia)


  • Opalia Pharma

  • UNIMED Laboratories


  • Taha Pharma

  • Cytopharma

For more information on this report, visit


Leave A Reply